Nordby E J, Wright P H
Department of Orthopaedic Surgery, University of Wisconsin, Madison.
Spine (Phila Pa 1976). 1994 Nov 15;19(22):2578-83. doi: 10.1097/00007632-199411001-00014.
This study was designed to determine the current experience in the use of chymopapain injection in the treatment of herniated intervertebral discs by analyzing reports appearing between 1985 and 1993. Forty-five clinical studies included 7,335 patients treated worldwide, some including comparisons to open laminectomy/discectomy and others to percutaneous discectomy.
Because controversy persists after 30 years of clinical use of chymopapain, the results of current experience should establish the efficacy for those who want to consider chemonucleolysis as a treatment for a herniated nucleus pulposus.
There is the suggestion that use of other than conservative treatment is made only to achieve a better result in the short term. The selection of type of treatment will depend on contraindications, with failures of chemonucleolysis found largely in those having spinal stenosis or sequestrated discs. Worker compensation patients respond less successfully than those with better motivation.
The 45 studies were analyzed for determination of successful outcome and divided into 16 with more than 100 patients, 13 with less than 100 patients and 16 with comparison to other treatments.
Individual success rates exceeded 60% whereas cohort total averaged 76%. In studies comparing chemonucleolysis with open discectomy, success rate averaged 76.2% as compared with 88% for open surgery. In two other studies, percutaneous discectomy was less successful than chemonucleolysis. Where included, duration of hospitalization showed less time and thus less costs for chemonucleolysis. Return to work complications showed time off slightly less for chemonucleolysis than for laminectomy.
Chemonucleolysis, though somewhat less effective than open discectomy, can be successfully and safely used in about four of five carefully selected patients without the trauma, risks, and subsequent fibrosis associated with lumbar disc surgery.
本研究旨在通过分析1985年至1993年间发表的报告,确定目前使用木瓜凝乳蛋白酶注射治疗椎间盘突出症的经验。45项临床研究纳入了全球范围内接受治疗的7335例患者,其中一些研究包括与开放性椎板切除术/椎间盘切除术以及与经皮椎间盘切除术的比较。
由于木瓜凝乳蛋白酶临床应用30年后仍存在争议,当前经验的结果应为那些考虑将化学髓核溶解术作为治疗髓核突出症方法的人确立其疗效。
有观点认为,采用非保守治疗仅为在短期内取得更好疗效。治疗方式的选择将取决于禁忌症,化学髓核溶解术的失败主要见于患有椎管狭窄或游离椎间盘的患者。工伤赔偿患者的治疗效果不如积极性更高的患者。
对45项研究进行分析以确定成功结果,并分为16项患者超过100例的研究、13项患者少于100例的研究以及16项与其他治疗方法比较的研究。
个体成功率超过60%,而队列总体平均成功率为76%。在将化学髓核溶解术与开放性椎间盘切除术进行比较的研究中,化学髓核溶解术的平均成功率为76.2%,而开放性手术为88%。在另外两项研究中,经皮椎间盘切除术的成功率低于化学髓核溶解术。若有相关数据,化学髓核溶解术的住院时间更短,因此费用更低。恢复工作后的并发症方面,化学髓核溶解术的休假时间略少于椎板切除术。
化学髓核溶解术虽然比开放性椎间盘切除术效果稍差,但约五分之四精心挑选的患者可成功且安全地使用,且无腰椎间盘手术相关的创伤、风险及后续纤维化问题。